Increasing evidence had shown that MGP, Fetuin-A, Rankl, BMP2, Annexin-A2, and other molecules were related to vascular calcification, and the level of calcification promoters was often increased and accompanied by a decrease in calcification inhibitors in patients with CKD (Chen et al., 2008; Marechal et al., 2011; Viegas et al., 2015; Roumeliotis et al., 2020). This evidence concerns the gene MGP and chronic kidney disease.